Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;17(2):89-102.
doi: 10.4110/in.2017.17.2.89. Epub 2017 Apr 20.

Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review

Mehdi Najar  1 , Mohammad Krayem  2 , Nathalie Meuleman  1 , Dominique Bron  1 , Laurence Lagneaux  1
Affiliations
Review

Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review

Mehdi Najar et al. Immune Netw. 2017 Apr.

Abstract

Mesenchymal Stromal Cells (MSCs) are potential cellular candidates for several immunotherapy purposes. Their multilineage potential and immunomodulatory properties make them interesting tools for the treatment of various immunological diseases. However, depending on the local microenvironment, diverse biological functions of MSCs can be modulated. Indeed, during infections such as obtained following TLR-agonist engagement (called as TLR priming), the phenotype, multilineage potential, hematopoietic support and immunomodulatory capacity of MSCs can present critical changes, which could further affect their therapeutic potential. Thus, for appropriate clinical application of MSCs, it is important to well know and understand these effects in particular during infectious episodes and to find the suitable experimental settings to study that. Pre-stimulation of MSCs with a specific TLR ligand may serve as an effective priming step to modulate one of its function to achieve a desired therapeutic issue.

Keywords: Hematopoietic support; Immunomodulation; MSCs; Multilineage potential; Phenotype; Priming; TLR.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors declare no potential conflicts of interest.

Figures

Figure 1
Figure 1. Activation of TLRs on MSCs.
Figure 2
Figure 2. The MSC response following to TLR priming.
See this image and copyright information in PMC

References

    1. Fayyad-Kazan M, Fayyad-Kazan H, Lagneaux L, Najar M. The potential of mesenchymal stromal cells in immunotherapy. Immunotherapy. 2016;8:839–842. - PubMed
    1. Hass R, Kasper C, Bohm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9:12. - PMC - PubMed
    1. El Omar R, Beroud J, Stoltz JF, Menu P, Velot E, Decot V. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? Tissue Eng Part B Rev. 2014;20:523–544. - PubMed
    1. Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp. 1988;136:42–60. - PubMed
    1. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9:11–15. - PMC - PubMed